Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

PET of CD105 expression with a 61/64Cu-labeled Fab antibody fragment

Yin Zhang, Hao Hong, Hakan Orbay, Todd Barnhart, Charles Theuer and Weibo Cai
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 395;
Yin Zhang
1University of Wisconsin - Madison, Madison, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hao Hong
1University of Wisconsin - Madison, Madison, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hakan Orbay
1University of Wisconsin - Madison, Madison, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd Barnhart
1University of Wisconsin - Madison, Madison, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Theuer
2TRACON Pharmaceuticals, San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weibo Cai
1University of Wisconsin - Madison, Madison, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

395

Objectives To generate and characterize the Fab fragment of TRC105, a monoclonal antibody that binds with high affinity to human and murine CD105 (i.e. endoglin), and investigate its potential for positron emission tomography (PET) imaging of tumor angiogenesis in a mouse model after 61/64Cu-labeling.

Methods TRC105-Fab was generated by enzymatic papain digestion. The integrity and CD105 binding affinity of TRC105-Fab was evaluated before NOTA (i.e., 1,4,7-triazacyclononane-1,4,7-triacetic acid) conjugation and 61/64Cu-labeling. Serial PET imaging and biodistribution studies were carried out in the 4T1 murine breast cancer model to quantify tumor targeting and normal organ distribution of 61/64Cu-NOTA-TRC105-Fab. Blocking studies with TRC105, as well as histological assessment, were performed to confirm CD105 specificity of the tracer.

Results TRC105-Fab was produced with high purity through papain digestion of TRC105, as confirmed by SDS-PAGE, HPLC analysis, and mass spectrometry. 61/64Cu-labeling of NOTA-TRC105-Fab was achieved with good yield and specific activity. PET imaging revealed rapid uptake of 64Cu-NOTA-TRC105-Fab in the 4T1 tumor (3.6±0.4, 4.2±0.5, 4.9±0.3, and 4.6±0.8 %ID/g at 0.5, 2, 5, and 24 h post-injection respectively; n = 4). Since tumor uptake peaked soon after tracer injection, 61Cu-labeled TRC105-Fab was also able to provide good tumor contrast at 3 and 8 h post-injection. CD105 specificity of the tracer was confirmed with blocking and histology studies.

Conclusions 61/64Cu-NOTA-TRC105-Fab exhibited prominent and target specific uptake in the 4T1 tumor, as seen with PET. The use of a Fab fragment led to much faster tumor uptake (peak uptake was noted a few hours after injection) compared to radiolabeled intact antibody, which may be translated into same day immunoPET imaging for clinical investigation. The use of 61Cu, which has higher β+ branching ratio than 64Cu (62% vs 17%), is optimal for small proteins like Fab. It offers stronger signal intensity and requires a lower tracer dose for PET imaging than 64Cu, which will facilitate clinical translation.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 54, Issue supplement 2
May 2013
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PET of CD105 expression with a 61/64Cu-labeled Fab antibody fragment
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PET of CD105 expression with a 61/64Cu-labeled Fab antibody fragment
Yin Zhang, Hao Hong, Hakan Orbay, Todd Barnhart, Charles Theuer, Weibo Cai
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 395;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PET of CD105 expression with a 61/64Cu-labeled Fab antibody fragment
Yin Zhang, Hao Hong, Hakan Orbay, Todd Barnhart, Charles Theuer, Weibo Cai
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 395;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Physiological distribution of 68Ga-DOTA-TATE: an atlas of standardized uptake values
  • ROC analysis for xSPECT Bone
  • Long-term outcomes of differentiated thyroid cancer with only lung metastasis and the prognostic factors
Show more Oncology: Basic, Translational & Therapy

Basic Science (Oncology): Molecular Characterization

  • Development of ABT-806i, a Kit-formulated 111In-ABT-806 antibody directed to EGFR for tumor imaging
  • Comparison of intratumoral distribution of 18F-FMISO and 64Cu-ATSM with regions genetically responding to hypoxia by quantitative cluster analyses
  • 18F-Misonidazole PET imaging hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer
Show more Basic Science (Oncology): Molecular Characterization

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire